Stephen Letrent is the founder of TORL BioTherapeutics. TORL BioTherapeutics has raised $450M in total funding. Latest round: Series C.
Stephen Letrent is a biopharmaceutical professional who has been Chief Development Officer at TORL BioTherapeutics since March 2020. He leads the clinical development of novel cancer therapeutics and also serves on the Scientific Advisory Board at Talus Bio. TORL BioTherapeutics is a clinical-stage company developing antibody-based immunotherapies for cancer patients.
Full founder directory · Investor directory · Company funding database · Fundraising library